Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX).
The structural definition of human tumor antigens recognized by the autologous host has been a long-standing challenge in tumor immunology. The growing list of human tumor antigens recognized by autologous antibodies or cytotoxic T lymphocytes provides convincing evidence for immune recognition of cancer by the host of origin, as well as attractive targets for vaccine-based approaches to cancer therapy. In this regard, an approach called SEREX (serological analysis of recombinant cDNA expression libraries) has broad applicability to the analysis of the humoral immune response to cancer antigens. This method involves immunoscreening cDNA libraries prepared from tumor specimens with sera from cancer patients in order to identify gene products recognized by IgG antibody. Clones identified by SEREX can be directly sequenced, providing immediate structural definition of the antigenic target, and their expression profiles can be readily determined, providing information regarding their tissue distribution. Application of this technique has led to the discovery of a number of provocative tumor antigens.
Scanlan
Matthew J
MJ
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm / Q000032:analysis*; D018076:DNA, Complementary; D015723:Gene Library; D006801:Humans; D007106:Immune Sera; D009369:Neoplasms / Q000276:immunology*; D011994:Recombinant Proteins
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D018076:DNA, Complementary; D007106:Immune Sera; D011994:Recombinant Proteins